A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors

This early-phase study is testing a new experimental drug called HLX43 in combination with an immunotherapy drug called serplulimab for people with advanced or metastatic solid tumors (cancers in organs or tissues) that have not responded to standard treatments. **You may be eligible if...** - You are between 18 and 75 years old - You have a confirmed advanced or metastatic solid tumor - Standard treatment options have been exhausted or are no longer working - Your general health is adequate to participate (as assessed by your doctor) - You are willing and able to follow all study procedures **You may NOT be eligible if...** - You have significant heart, liver, or kidney problems - You have active autoimmune disease or are on immune-suppressing medications - You have untreated brain metastases - You have received recent immunotherapy that caused serious side effects - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.